Recent Company News

• 11:06 AM ET Nov 05, 2026
  

  Genmab reports Q3 net income $342M vs FactSet $218.5M [12 est, $148-301.0M] (DKK 3635.00, 0.00)

• 09:00 AM ET Oct 29, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:06 PM ET Oct 29, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:44 PM ET Nov 04, 2026
  

  StreetAccount Sector Summary: Healthcare Monthly Recap - October 2026

• 09:10 AM ET Nov 04, 2026
  

  Genmab to present results from comprehensive Epcoritamab development program highlighting potential across b-cell malignancies at the 2026 ASH annual meeting (DKK 3712.00, -7.00)

• 02:10 PM ET Nov 01, 2026
  

  Technical Reactions to GMAB Trends in Macro Strategies

• 11:56 PM ET Oct 30, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 04:39 AM ET Oct 29, 2026
  

  Genmab downgraded to hold from buy at Sydbank (pre-European open) (DKK 3814.00, -54.00)